Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Director Sells 87,425 Shares of Stock

by · The Cerbat Gem

Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) Director Luke Evnin sold 87,425 shares of the business’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $0.45, for a total transaction of $39,341.25. Following the transaction, the director directly owned 831,635 shares of the company’s stock, valued at approximately $374,235.75. This represents a 9.51% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

  • On Tuesday, May 26th, Luke Evnin sold 67,950 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.47, for a total transaction of $31,936.50.
  • On Thursday, May 21st, Luke Evnin sold 36,387 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.42, for a total transaction of $15,282.54.
  • On Wednesday, May 20th, Luke Evnin sold 85,895 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.43, for a total transaction of $36,934.85.
  • On Tuesday, May 19th, Luke Evnin sold 62,970 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.45, for a total transaction of $28,336.50.
  • On Monday, May 18th, Luke Evnin sold 22,184 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.50, for a total transaction of $11,092.00.
  • On Tuesday, May 12th, Luke Evnin sold 67,885 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total transaction of $43,446.40.
  • On Monday, May 11th, Luke Evnin sold 33,948 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.67, for a total transaction of $22,745.16.
  • On Friday, May 8th, Luke Evnin sold 305,741 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.70, for a total transaction of $214,018.70.
  • On Thursday, May 7th, Luke Evnin sold 79,086 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total transaction of $49,824.18.
  • On Wednesday, May 6th, Luke Evnin sold 14,635 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.66, for a total transaction of $9,659.10.

Werewolf Therapeutics Stock Performance

NASDAQ:HOWL traded up $0.02 during midday trading on Tuesday, reaching $0.46. 797,900 shares of the stock traded hands, compared to its average volume of 465,332. The company has a fifty day moving average of $0.77 and a 200 day moving average of $0.77. Werewolf Therapeutics, Inc. has a 12 month low of $0.40 and a 12 month high of $2.38. The stock has a market capitalization of $22.51 million, a P/E ratio of -0.37 and a beta of 0.41.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04. On average, analysts predict that Werewolf Therapeutics, Inc. will post -1.29 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on HOWL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Monday, April 20th. Wall Street Zen lowered shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Two research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $3.75.

Read Our Latest Research Report on HOWL

Institutional Trading of Werewolf Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Regal Investment Advisors LLC grew its position in shares of Werewolf Therapeutics by 93.3% in the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after buying an additional 25,389 shares during the period. Vontobel Holding Ltd. grew its position in shares of Werewolf Therapeutics by 66.7% in the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after buying an additional 24,003 shares during the period. Qube Research & Technologies Ltd purchased a new stake in shares of Werewolf Therapeutics in the 2nd quarter worth about $48,000. AQR Capital Management LLC purchased a new stake in shares of Werewolf Therapeutics in the 1st quarter worth about $79,000. Finally, Bridgeway Capital Management LLC grew its position in shares of Werewolf Therapeutics by 157.7% in the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after buying an additional 62,414 shares during the period. 64.84% of the stock is owned by hedge funds and other institutional investors.

About Werewolf Therapeutics

(Get Free Report)

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.

Featured Articles